2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-174858
    dASK1-VHL 98%
    dASK1-VHL is an orally active PROTAC degrader targeting ASK1. dASK1-VHL can effectively bind VHL and promote the selective degradation of ASK1. dASK1-VHL effectively reduces ASK1 protein levels, inhibits the activation of p38 MAPK, and reduces liver lipid content. dASK1-VHL provides new ideas for the study of Metabolic dysfunction-associated steatohepatitis (MASH).
    dASK1-VHL
  • HY-174887
    THR-β agonist 9 2920045-74-3 98%
    THR-β agonist 9 is a potent, selective, and His435 mutation-sensitive THR-β (EC50: 3.2 nM) agonist. THR-β agonist 9 has moderate selectivity (approximately 10-fold) and good activation capacity (EC50: 134.2 nM to 515.5 nM) for multiple His435 mutants (H435A, H435Y, and H435R). THR-β agonist 9 has the potential to be used in the study of dyslipidemia, metabolic dysfunction-associated steatohepatitis (MASH), or resistance to thyroid hormone (RTH).
    THR-β agonist 9
  • HY-174913
    Factor B-IN-5 1644670-23-4 98%
    Factor B-IN-5 is an orally active complement factor B (CFB) inhibitor. Factor B-IN-5 alleviates kidney damage in diabetes nephropathy by inhibiting the over activation of complement system and improving mitochondrial function. Factor B-IN-5 can improve renal tubulointerstitial inflammation and fibrosis. Factor B-IN-5 can be used for research on diabetic nephropathy.
    Factor B-IN-5
  • HY-175005
    CF-Carvacrol 98%
    CF-Carvacrol is an orally active lipid-lowering agent synthesized by merging the pharmacophores of Carvacrol (HY-N0711) and Clofibric acid (HY-B1415). CF-Carvacrol has a good affinity for PPAR-α. CF-Carvacrol has significant hypolipidemic activity and may exert antioxidant and anti-inflammatory activity by activating the Nrf2/HO-1 signaling pathway to reduce liver injury. CF-Carvacrol can be used for the study of CF-induced liver damage.
    CF-Carvacrol
  • HY-17504C
    (3R,5R)-Rosuvastatin 1094100-06-7 98%
    (3R,5R)-Rosuvastatin is the (3R,5R)-enantiomer of Rosuvastatin. Rosuvastatin is a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM. Rosuvastatin potently blocks human ether-a-go-go related gene (hERG) current with an IC50 of 195 nM. Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin is very effective in lowering low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels.
    (3R,5R)-Rosuvastatin
  • HY-17504D
    (3S,5R)-Rosuvastatin 1242184-42-4 98%
    (3S,5R)-Rosuvastatin is the (3S,5R)-enantiomer of Rosuvastatin. Rosuvastatin is a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM. Rosuvastatin potently blocks human ether-a-go-go related gene (hERG) current with an IC50 of 195 nM. Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin is very effective in lowering low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels.
    (3S,5R)-Rosuvastatin
  • HY-175053
    Pasireotide (aspartate) TFA
    Pasireotide (aspartate) TFA, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide (aspartate) TFA can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide (aspartate) TFA also exhibits antisecretory, antiproliferative, and proapoptotic activity.
    Pasireotide (aspartate) TFA
  • HY-175070
    D-myo-Inositol-2,4,5-triphosphate sodium salt
    D-myo-Inositol-2,4,5-triphosphate (Ins(2,4,5)P3) (sodium salt) is a second messenger produced in cells by phospholipase C-mediated hydrolysis of phosphatidylinositol-4,5-biphosphate. D-myo-Inositol-2,4,5-triphosphate (sodium salt) can open calcium channels and increase intracellular calcium upon binding to its receptors on the endoplasmic reticulum. D-myo-Inositol-2,4,5-triphosphate (sodium salt) also acts as a partial agonist at rat hepatic IP3 receptors. D-myo-Inositol-2,4,5-triphosphate (sodium salt) can be studied in research on calcium ions signaling pathway.
    D-myo-Inositol-2,4,5-triphosphate sodium salt
  • HY-175076
    Globotriaosylceramide (non-hydroxy) (porcine RBC)
    Globotriaosylceramide (non-hydroxy) (porcine RBC) is a glycosphingolipid found in the cell membranes of mammals. Globotriaosylceramide (non-hydroxy) (porcine RBC) is the core pathogenic molecule of Fabry disease, and its level can be downregulated by supplementing α-galactosidase A. Globotriaosylceramide (non-hydroxy) (porcine RBC) amplifies B-cell receptor signals by regulating the localization of co-receptor CD19, and can be used as a vaccine adjuvant, capable of guiding the generation of broad-spectrum and cross-protective antibody responses. Globotriaosylceramide (non-hydroxy) (porcine RBC) promotes wound healing and reduces scar formation by regulating fibroblast heterogeneity.
    Globotriaosylceramide (non-hydroxy) (porcine RBC)
  • HY-175079
    (±)17(18)-DiHETE 168111-97-5
    (±)17(18)-DiHETE is an oxidized lipid and a metabolite of Eicosapentaenoic Acid (HY-B0660), an orally active omega-3 long-chain polyunsaturated fatty acid (ω-3 LC-PUFA).
    (±)17(18)-DiHETE
  • HY-175084
    1-Hexadecyl lysophosphatidic acid sodium
    1-Hexadecyl lysophosphatidic acid (1-Hexadecyl LPA) sodium, an ether analog of lysophosphatidic acid (LPA), is a LPA receptor activator.
    1-Hexadecyl lysophosphatidic acid sodium
  • HY-175098
    (±)14(15)-DiHETE 168026-81-1
    (±)14(15)-DiHETE, an oxylipin, is a metabolite of Eicosapentaenoic Acid (HY-B0660). Eicosapentaenoic Acid is an orally active Omega-3 long-chain polyunsaturated fatty acid (ω-3 LC-PUFA).
    (±)14(15)-DiHETE
  • HY-175106
    8-(4-Azidophenacylthio) NAD+ sodium
    8-(4-Azidophenacylthio) NAD+ sodium is a clickable form of NAD+ (HY-B0445). NAD+ is a coenzyme that transfers hydrogen ions.
    8-(4-Azidophenacylthio) NAD+ sodium
  • HY-175128
    8-(2-Aminoethylthio)guanosine-5'-O-triphosphate sodium
    8-(2-Aminoethylthio)guanosine-5'-O-triphosphate (8-AET-GTP) is a GTP (HY-113225) derivative. GTP is the energy substrate for protein synthesis and gluconeogenesis.
    8-(2-Aminoethylthio)guanosine-5'-O-triphosphate sodium
  • HY-175149
    2-Fluorodeoxyarbutin 170795-16-1
    2-Fluorodeoxyarbutin, a derivative of Deoxyarbutin (HY-B1461), is a tyrosine hydroxylase and dopa oxidase inhibitor. 2-Fluorodeoxyarbutin inhibits melanin synthesis in intact melanocytes. 2-Fluorodeoxyarbutin can be used for the strudy of skin lightening or for ameliorating hyperpigmented lesions.
    2-Fluorodeoxyarbutin
  • HY-175151
    2-Amino-3-[2-(tert-butoxy)-2-oxoethoxy]propanoic acid
    2-Amino-3-[2-(tert-butoxy)-2-oxoethoxy]propanoic acid (O-(2-(tert-Butoxy)-2-oxoethyl)serine) is a Serine (HY-N0650) derivative. Serine is an amino acid.
    2-Amino-3-[2-(tert-butoxy)-2-oxoethoxy]propanoic acid
  • HY-175170
    α-Glucosidase-IN-95
    α-Glucosidase-IN-95 (Compound 21c) is a competitive α-Glucosidase inhibitor with an IC50 of 0.44  μM. α-Glucosidase-IN-95 has a significant inhibitory potency without cytotoxicity to normal cells. α-Glucosidase-IN-95 can be used for metabolic disorders like diabetes mellitus research.
    α-Glucosidase-IN-95
  • HY-175235
    MEK4 IN-3
    MEK4 IN-3 (Compound 39) is a selective MEK4 inhibitor with IC50s of 78   and 2920 nM for MEK4 and RSK4, respectively. MEK4 IN-3 reduces toxicity in cells. MEK4 IN-3 can be used for liver failure, particularly nonalcoholic fatty liver disease (NAFLD) research.
    MEK4 IN-3
  • HY-175263
    Aminochalcone 4AAF 38239-51-9 98%
    Aminochalcone 4AAF is a neuroprotective agent that exerts anxiolytic effects through GABAA and 5-HT receptors. Aminochalcone 4AAF has high selectivity for 5-HT3A and 5-HT2C receptors, and stimulates allosteric behavior toward the 5-HT2A receptor. Aminochalcone 4AAF shows hypoglycemic effects and reduces the level of ROS in the liver. Aminochalcone 4AAF delays the clonic stage of the epileptic seizures . Aminochalcone 4AAF can be used in the study of anxiety, hyperglycemia, and seizures.
    Aminochalcone 4AAF
  • HY-175267
    PXR Ligand 3 2733559-38-9
    PXR Ligand 3 is a PXP ligand. PXR Ligand 3 can be used to synthesize PROTAC MI1013 (HY-175266).
    PXR Ligand 3
Cat. No. Product Name / Synonyms Application Reactivity